Course of graves disease in interferon-treated patients with chronic hepatitis C virus infection and in uninfected patients

Journal of Investigative Medicine

Volumn 61, Issue 8, 2013, Pages 1173-1177

  Minelli, Roberta ^a   Spagnoli, Francesca ^a   Marchesi, Elisabetta ^a   Venturi, Nicola ^a   Marina, Michela ^a   Orlandini, Alessandra ^b   Zardo, Marianna ^a   Ferrari, Carlo ^b   Ceresini, Graziano ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Graves disease; HCV hepatitis; Interferon alfa therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; THIAMAZOLE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROID ANTIBODY; THYROID HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE COMPARISON; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MALE; MONOTHERAPY; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; ULTRASOUND SCANNER; ANTIBODY BLOOD LEVEL; CHRONIC HEPATITIS C; MIDDLE AGED; THYROID HORMONE BLOOD LEVEL;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; GRAVES DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896788478     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000000     Document Type: Article

References (35)

1. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36(4):1051-1066.
2. Nadeem A, Hussain MM, Aslam M, et al. Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C. Hepat Mon. 2010;10(2):132-140.
3. Wong V, Fu AX, George J, et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf). 2002;56(6):793-798.
4. Fentiman IS, Thomas BS, Balkwill FR, et al. Primary hipothyroidism associated with interferon therapy of breast cancer. Lancet. 1985; 1(8438):1166.
5. Burman P, Toterman TH, Oberg K, et al. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986;63(5):1086-1090.
6. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009;23(6):703-712.
7. Foldes I, David K, Horvath G, et al. Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha. Orv Hetil. 2004; 145(23):1211-1216.
8. Morisco F, Mazziotti G, Rotondi M. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis. 2001;33(3):247-253.
9. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164(21):2371-2376.
10. Vasiliadis T, Anagnostis P, Nalmpantidis G, et al. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore. 2011;40(9): 394-400.
11. Carella C, Mazziotti G, Amato G, et al. Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89(8):3656-3661.
12. Koh LK, Greenspan FS, Yeo PP. Interferon-induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997;7(6):891-896.
13. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 13(6):547-551.
14. Fernandez-Soto L, Gonzales A, Escobar-Jimenez F. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158(13): 1445-1448.
15. Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alpha-induced thyroid disfunction in patients with chronic hepatitis C. Eur J Endocrinol. 2000;142(5):431-437.
16. Floreani A, Chiaramonte M, Greggio NA, et al. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol. 1998;30(1):71-76.
17. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hapatitis with interferon alfa. Gastroenterology. 1992;102(6):2155-2160.
18. Tran A, Quaranta JF, Benzaken S. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18(2):253-257.
19. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101(5):482-487.
20. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV related chronic hepatitis: a prospective studies. J Endocrinol Invest. 2002;25(7):624-630.
21. Dalgard O, Bjøro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251(5):400-406.
22. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499.
23. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43(1):55-68.
24. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
25. Minelli R, Roti E. Interferone e tireopatie. Endocrinologo. 2000;1(2): 63-68.
26. Villanueva RB, Brau N. Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid. 2002;12(8): 737-738.
27. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alfa induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86(5):1925-1929.
28. Davies FT. Graves'disease: pathogenesis. In: Utiger RD, Braveman LE, eds. The Thyroid. Philadelphia, PA: Lippincott Williams & Wilkins; 2000, pp 518-531.
29. Minelli R, Coiro V, Valli MA, et al. Graves' disease in interferon-α-treated and untreated patients with chronic hepatitis C virus infection. J Investig Med. 2005;53(1):26-30.
30. Corssmit EP, De Metz J, Sauerwein HP, et al. Biologic responses to IFN-α administration in humans. J Interferon Cytokine Res. 2000; 20(12):1039-1047.
31. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58(12):2489-2499.
32. Ajjan RA, Watson PF, McIntosh RS, et al. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol. 1996; 105(3):523-528.
33. Mandac JC, Chaundry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: towards a new classification. Hepatology. 2006;43(4):661-672.
34. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132(5): 587-593.
35. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest. 1997;20(7):374-380.